Literature DB >> 18200008

Drug insight: autoimmune effects of medications-what's new?

Anne-Barbara Mongey1, Evelyn V Hess.   

Abstract

Autoantibodies and lupus-like syndromes can develop following the use of certain medications; however, although many patients develop autoantibodies, only a minority develop clinical features. Although these autoantibodies primarily consist of antinuclear and antihistone antibodies, additional types of antibody, such as antineutrophil cytoplasmic antibodies and anti-double-stranded DNA antibodies, have been reported in association with minocycline and tumor necrosis factor inhibitor therapy. Clinical features of drug-related lupus usually consist of constitutional symptoms, arthralgias, arthritis, myalgias and serositis, although cutaneous manifestations have been reported in association with the use of tumor necrosis factor inhibitors. Typically, clinical features resolve with discontinuation of the medication, although antibodies can persist for months or years. Arthralgias and inflammatory arthritis have also been reported in association with the use of aromatase inhibitors and other biologic agents such as interleukins and interferons.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18200008     DOI: 10.1038/ncprheum0708

Source DB:  PubMed          Journal:  Nat Clin Pract Rheumatol        ISSN: 1745-8382


  13 in total

Review 1.  [Biologics. New drugs, new adverse reactions].

Authors:  J C Prinz
Journal:  Hautarzt       Date:  2010-08       Impact factor: 0.751

2.  A role for muscarinic receptors in neutrophil extracellular trap formation and levamisole-induced autoimmunity.

Authors:  Carmelo Carmona-Rivera; Monica M Purmalek; Erica Moore; Meryl Waldman; Peter J Walter; H Martin Garraffo; Karran A Phillips; Kenzie L Preston; Jonathan Graf; Mariana J Kaplan; Peter C Grayson
Journal:  JCI Insight       Date:  2017-02-09

3.  Lupus-like syndrome attributable to anti-tumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic.

Authors:  David A Wetter; Mark D P Davis
Journal:  Mayo Clin Proc       Date:  2009-11       Impact factor: 7.616

4.  Minocycline attenuates ethanol-induced cell death and microglial activation in the developing spinal cord.

Authors:  Zhenhua Ren; Xin Wang; Mei Xu; Jacqueline A Frank; Jia Luo
Journal:  Alcohol       Date:  2018-12-07       Impact factor: 2.405

Review 5.  The safety and side effects of monoclonal antibodies.

Authors:  Trevor T Hansel; Harald Kropshofer; Thomas Singer; Jane A Mitchell; Andrew J T George
Journal:  Nat Rev Drug Discov       Date:  2010-03-22       Impact factor: 84.694

Review 6.  The importance of NAD in multiple sclerosis.

Authors:  W Todd Penberthy; Ikuo Tsunoda
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

7.  Prescription medication use and antinuclear antibodies in the United States, 1999-2004.

Authors:  Gregg E Dinse; Christine G Parks; Helen C S Meier; Caroll A Co; Edward K L Chan; Todd A Jusko; James Yeh; Frederick W Miller
Journal:  J Autoimmun       Date:  2018-05-18       Impact factor: 7.094

8.  Vasculitis associated with tumor necrosis factor-α inhibitors.

Authors:  Olayemi Sokumbi; David A Wetter; Ashima Makol; Kenneth J Warrington
Journal:  Mayo Clin Proc       Date:  2012-07-13       Impact factor: 7.616

9.  Onset of lupus like syndrome in patients with spondyloarthritis treated with anti-TNF-α.

Authors:  Eduardo Puertas-Abreu; Elaudi Rodríguez Polanco; Miriam Azocar; Luis Antonio Mundarain; Concepción Morelia Nuñez-Sotelo; Rafael Montaño; Freddy Herrera Vivas; Zair Tovar Noguera; Francisco Marín; Omar Bellorin; José Gregorio Rivas; Eduardo Toro; Eugenia Benzaquen; Mayra Rauseo; Luis Arturo Gutiérrez González
Journal:  Int Arch Med       Date:  2012-02-15

10.  A Systematic Review of Drug-Induced Pemphigoid.

Authors:  Matthew J Verheyden; Asli Bilgic; Dédée F Murrell
Journal:  Acta Derm Venereol       Date:  2020-08-17       Impact factor: 3.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.